<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02611700</url>
  </required_header>
  <id_info>
    <org_study_id>BPL-IST-ESO-057</org_study_id>
    <nct_id>NCT02611700</nct_id>
  </id_info>
  <brief_title>Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma</brief_title>
  <official_title>An Prospective, Multicenter, Double-blind, Randomized, Controlled Clinical Study of Nimotuzumab Combined With Paclitaxel and Cisplatin as First-line Treatment of Metastatic Esophageal Squamous Cell Carcinomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotech Pharmaceutical Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotech Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study is designed as a phase 3,multicenter, double-blind, randomized,
      controlled study,to evaluate the efficacy and safety of nimotuzumab combined with
      paclitaxel+cisplatin（TP) compared with TP as first-line treatment for the metastatic
      esophageal squamous carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical study is designed as a phase 3,multicenter, double-blind, randomized,
      controlled study,to evaluate the efficacy and safety of nimotuzumab combined with TP compared
      with TP as first-line treatment for the metastatic esophageal squamous carcinoma.The main
      endpoint is OS.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median time of overall survival(OS)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Record all the survival status of each patient and calculate the median OS of all the patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median time of progression-free survival（PFS）</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>PFS is the time that passes from the date of signing Informed Consent Form（ICF）to the data on which &quot;progresses&quot; or the date on which the patient dies from any cause. The definition of &quot;progression&quot; since this generally involves imaging techniques(CT,MRI,et al).The Response Evaluation Criteria In Solid Tumors (RECISIT) 1.1 criteria will be used to evaluate &quot;progression&quot;.The imaging evaluation will be done every 6 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate（ORR）</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>This wil be evaluated by RECISIT 1.1 criteria.It is dependent on imaging evaluation which will be done every 6 weeks. ORR is the percent of the patient who is evaluated as complete response(CR) or partial response (PR),that is (CR+PR)%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>baseline;once every 6 weeks until progression(6 weeks,12 weeks,18 weeks,up to 52 weeks)</time_frame>
    <description>Using the European Organization for Research and Treatment of Cancer（EORTC）quality of life questionnaire（QLQ）-C30（Version3.0）and EORTC QLQ - OES18 to evaluate the quality of life of patients. The patients will fill this questionnaire when signing the ICF(as baseline) and every 6 weeks during treatment,until disease progression,up to 52 weeks. The progression is from date of randomization until the date of first documented progression or date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 30 days after last administration of nimotuzumab</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">504</enrollment>
  <condition>Esophageal Squamous Cell Carcinomas</condition>
  <arm_group>
    <arm_group_label>experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nimotuzumab+TP(paclitaxel+cisplatin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + TP(paclitaxel+cisplatin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nimotuzumab</intervention_name>
    <description>400mg,day1,weekly,until disease progression or toxicity</description>
    <arm_group_label>experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>175mg/m^2,for 3 hour(Peripherally Inserted Central Catheter,PICC),day1,21 days for a cycle ,until disease progression or toxicity，maximum duration is 6 cycles.</description>
    <arm_group_label>experimental group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
    <other_name>Paclitaxel Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>60mg/m^2,day1，21 days for a cycle ,until disease progression or toxicity,maximum duration is 6 cycles.</description>
    <arm_group_label>experimental group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
    <other_name>Cisplatin for Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>400mg,day1,weekly,until disease progression or toxicity</description>
    <arm_group_label>control group</arm_group_label>
    <other_name>Nimotuzumab Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Voluntary and sign a consent form;

          2. Age≥18 years;

          3. Histological diagnosis as metastatic esophageal squamous cell carcinoma, including:
             (1)Naked metastatic esophageal cancer：have no opportunity to receive any radical
             surgery or radical radiation therapy (2) recurrent metastatic esophageal
             cancer：recurrence after surgery or adjuvant radiotherapy or radical concurrent radio
             or radiochemotherapy,haven't received systemic chemotherapy and have measurable
             lesions outside radiotherapy target zone(3) recurrent metastatic esophageal
             cancer,more than 6 months after neoadjuvant or adjuvant chemotherapy;

          4. When patients need to receive palliative radiotherapy,the palliative radiotherapy
             should complete over 4 weeks and target lesions should outside the radiotherapy target
             zone(radiotherapy lesions include but not limited to primary tumors, bone, lymph
             nodes);

          5. According to RECIST 1.1 criteria, at least one measurable lesion exist;

          6. Expected survival time is over 3 months;

          7. Eastern Cooperative Oncology Group（ECOG）0 or 1;

          8. Normal bone marrow and hematopoietic function;total bilirubin acuities≤1.5×Upper Limit
             Of Normal（ULN）, creatinine≤1.0×ULN, aspartate aminotransferase（AST）/alanine
             aminotransferase（ALT）≤2.5×ULN, ALP≤5.0×ULN, creatinine clearance &gt; 60 ml/min, liver
             metastases patients: AST/ALT≤5.0×ULN;

          9. Take effective contraceptive measures when in growth period;

         10. Compliance is good.

        Exclusion Criteria:

          1. Have received any palliative chemotherapy for metastatic esophageal cancer

          2. Recurrence or metastasis after neoadjuvant chemotherapy or postoperative adjuvant &lt; 6
             months;

          3. Received any kinds of radiotherapy within 4 weeks;

          4. Patients who can received palliative radiotherapy and all lesions are in one radiation
             zone;

          5. Had received adjuvant/neoadjuvant therapy and have used paclitaxel within 6 months;

          6. Had received adjuvant/neoadjuvant therapy and the cumulative dose of cisplatin was
             over 300 mg/m2;

          7. Alone or combined with brain metastasis;

          8. No measurable tumor lesions;

          9. Combined with other primary malignant tumors (except cured skin basal cell carcinoma
             and cervical carcinoma in situ);

         10. Allergy to the component of investigational drugs;

         11. Patients who are receiving the treatment of chronic or multiple doses of
             corticosteroids (inhaled steroids or short-term oral cortisol according to the
             clinical indications were allowed);

         12. Haven't recovered to degree 1 from the toxicity of treatment before.

         13. Concomitant with severe cardiovascular diseases, such as uncontrol heart failure,
             coronary heart disease, cardiomyopathy, arrhythmia,high blood pressure or history of
             myocardial infarction within 5 years;

         14. Concomitant with serious complications, such as the activity of the digestive tract
             hemorrhage, perforation, severe jaundice, gastrointestinal obstruction, active
             clinical infection (&gt; 2 levels of infection standard);

         15. With chronic diarrhea disease and renal insufficiency;

         16. Have disease affecting cognition or mental abnormal;

         17. Have other severe acute or chronic diseases;

         18. Pregnancy or lactation women;

         19. Have participated in other clinical trials within 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Shen, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lin Shen, Dr</last_name>
    <phone>13911219511</phone>
    <email>lin100@medmail.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jun Zhou</last_name>
    <phone>13366152815</phone>
    <email>13366152815@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AnHui Provincial Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bin Hu</last_name>
      <phone>13515517331</phone>
      <email>hubin3756@sina.com</email>
    </contact>
    <investigator>
      <last_name>Bin Hu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Shen, Ph.D</last_name>
      <phone>13911219511</phone>
      <email>lin100@medmail.com.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jing Huang</last_name>
      <phone>13301056087</phone>
      <email>huangjingwg@163.com</email>
    </contact>
    <investigator>
      <last_name>Jing Huang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chinese PLA General Hospital Medical School of Chinese PLA</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guanghai Dai</last_name>
      <phone>13801232381</phone>
    </contact>
    <contact_backup>
      <last_name>Quanli Han</last_name>
      <phone>13366099651</phone>
      <email>hanquanli@aliyun.com</email>
    </contact_backup>
    <investigator>
      <last_name>Guanghai Dai</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Quanli Han</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chunmei Bai</last_name>
      <phone>13511071908</phone>
      <email>baichunmei@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Ning Jia</last_name>
      <phone>86-010-69158315</phone>
      <email>jianing@pumch.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Chunmei Bai</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ning Jia</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The 307 Hospital of Chinese People's Liberation Army</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jianming Xu</last_name>
      <phone>13910866712</phone>
    </contact>
    <contact_backup>
      <last_name>Yuling Chen</last_name>
      <phone>13871474131</phone>
    </contact_backup>
    <investigator>
      <last_name>Jianming Xu</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yuling Chen</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fujian Cancer Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cheng Huang</last_name>
      <phone>13905010379</phone>
      <email>cheng671@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Wu Zhuang</last_name>
      <phone>13809500871</phone>
      <email>zhuangwu2008@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Cheng Huang</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wu Zhuang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaoyan Lin</last_name>
      <phone>13950482366</phone>
      <email>xiaoyanlin@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Xiaoyan Lin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen University Cancer Center Sun Yat-Sen University Cancer Hospital</name>
      <address>
        <city>Guangzhou city</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruihua Xu, Dr</last_name>
      <phone>13922206676</phone>
      <email>xurh@sysucc.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Dongsheng Zhang</last_name>
      <phone>13719437860</phone>
      <email>zhangdsh@sysucc.org.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Ruihua Xu</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dongsheng Zhang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital of Shantou University Medical College</name>
      <address>
        <city>Shantou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yingcheng Lin</last_name>
      <phone>13802715900</phone>
      <email>linyingcheng@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Yingcheng Lin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yuxian Bai</last_name>
    </contact>
    <contact_backup>
      <last_name>Xiaoli Wei</last_name>
      <phone>15045449000</phone>
    </contact_backup>
    <investigator>
      <last_name>Yuxian Bai</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiaoli Wei</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qingxia Fan</last_name>
      <phone>13939039058</phone>
    </contact>
    <contact_backup>
      <last_name>Wang Ma</last_name>
      <phone>13663846306</phone>
      <email>doctormawang@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Qingxia Fan</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Liuxing Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wang Ma</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HuNan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xianli Yin</last_name>
      <phone>13319602869</phone>
    </contact>
    <contact_backup>
      <last_name>Shaofeng Jiang</last_name>
      <phone>13657356174</phone>
      <email>luoyi7824@126.com/jsfer@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>XianliXianli Yin</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shaofeng Jiang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>JiangSu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yongqian Shu</last_name>
      <phone>13951017570</phone>
    </contact>
    <contact_backup>
      <last_name>Lianke Liu</last_name>
      <phone>13951623290</phone>
      <email>liulianke@medmail.com.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Yongqian Shu</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lianke Liu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital ,JiangNan University</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dong Hua</last_name>
      <phone>13093087879</phone>
    </contact>
    <contact_backup>
      <last_name>Yong Mao</last_name>
      <phone>18651581690</phone>
      <email>mydoctorw-x@aliyu.com</email>
    </contact_backup>
    <investigator>
      <last_name>Dong Hua</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yong Mao</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jilin Cancer Hospital</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ying Cheng</last_name>
      <phone>13943012851</phone>
    </contact>
    <contact_backup>
      <last_name>Yanrong Wang</last_name>
      <phone>13944135005</phone>
      <email>381299269@qq.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ying Cheng</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yanrong Wang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LiaoNing Cancer Hospital</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tao Sun</last_name>
      <phone>18900917877</phone>
    </contact>
    <contact_backup>
      <last_name>Xiaoxin Wang</last_name>
      <phone>13304001989</phone>
      <email>wangxiaoxin_1234@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Tao Sun</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiaoxin Wang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Changhai Hospital of Shanghai</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mei Wang</last_name>
      <phone>13601810867</phone>
      <email>wangmeib0211@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Qiang Fu</last_name>
      <phone>13761297128</phone>
      <email>fumaye66@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mei Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qiang Fu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rui Jin Hospital Shanghai Jiao Tong University School Of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jun Zhang</last_name>
      <phone>13818332497</phone>
    </contact>
    <contact_backup>
      <last_name>Xinfang Shangguan</last_name>
      <phone>13816860375</phone>
      <email>clinner_haha@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jun Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xinfang Shangguan</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhongshan hospital of fudan university</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tianshu Liu</last_name>
      <phone>13681973996</phone>
    </contact>
    <contact_backup>
      <last_name>Yiwei Yu</last_name>
      <phone>13816730912</phone>
      <email>yuyiyi@zs.hospital.sh.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Tianshu Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yiwei Yu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated of Xi'an Communication University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Enxiao Li</last_name>
      <phone>13992819833</phone>
    </contact>
    <investigator>
      <last_name>Enxiao Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>XiJing Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xin Wang</last_name>
      <phone>13571826689</phone>
      <email>wangx@fmmu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Li Peng</last_name>
      <phone>029-84771794</phone>
      <email>xjyyllwyh@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Xin Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Li Peng</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West China Hospital,SiChuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Di Lu</last_name>
      <phone>13981935716</phone>
    </contact>
    <contact_backup>
      <last_name>Feng Peng</last_name>
      <phone>18980601767</phone>
      <email>pfwork@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Di Lu</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Feng Peng</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>TianJin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>TianJin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yi Yi</last_name>
      <phone>13752157916</phone>
    </contact>
    <contact_backup>
      <last_name>Jinhuai Xue</last_name>
      <phone>13502065304</phone>
      <email>xuejh1210@sina.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yi Yi</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jinhuai Xue</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hostpital School of Medicine,Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hongming Pan</last_name>
      <phone>13605716662</phone>
    </contact>
    <contact_backup>
      <last_name>Yu Zheng</last_name>
      <phone>13957179060</phone>
      <email>ZYubd@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hongming Pan</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yu Zheng</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The second Affiliated hospital of Zhejiang University School o</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ying Yuan</last_name>
      <phone>13858193601</phone>
    </contact>
    <contact_backup>
      <last_name>Caixia Dong</last_name>
      <phone>15068882349</phone>
      <email>dcx_1982@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ying Yuan</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caixia Dong</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang cancer hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yiping Zhang</last_name>
      <phone>13750881678</phone>
    </contact>
    <contact_backup>
      <last_name>Guangyuan Lou</last_name>
      <phone>13857108165</phone>
      <email>louguangyuan@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yiping Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guangyuan Lou</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2015</study_first_submitted>
  <study_first_submitted_qc>November 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2015</study_first_posted>
  <last_update_submitted>January 29, 2016</last_update_submitted>
  <last_update_submitted_qc>January 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

